NASDAQ OMX

Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel

Dela

 

Press Release

10 August 2017

Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel

Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the enrollment  of the first patient in the United States (US) as part of the Company's ongoing global Phase 2 MERECA (MEtastatic REnal Cell CArcinoma) trial. The trial is investigating the safety and efficacy of Immunicum's lead drug candidate ilixadencel, formerly known as INTUVAX, a cancer immune primer that is designed to specifically reactivate the patient's immune system to recognize and destroy tumor cells.

"With the first metastatic kidney cancer patient enrolled in the United States, we have achieved another important milestone for Immunicum. The continued expansion of our clinical program underscores the dedication of our team to realize ilixadencel's potential and to execute a global clinical trial including meeting all regulatory and manufacturing requirements in the US which are significant for a cell-based therapy," said Dr. Peter Suenaert, CMO of Immunicum.

"This is a significant step for Immunicum and I am very pleased that the first patient has been  enrolled in the US and that we are continuing to advance ilixadencel, our innovative immune priming cell therapy approach, through the clinic," said Carlos de Sousa, CEO of Immunicum.

The MERECA study is currently ongoing in eight European countries and is now rolled out in the US.  It examines the safety, tumor-specific immune activation and potential for clinical efficacy of two intratumoral doses of ilixadencel before surgical removal of the tumor-affected kidney and subsequent systemic treatment with sunitinib. In addition to analyzing the immune system activating effects of ilixadencel treatment, the study will also provide data on the clinical benefit through survival rate at 18 months and median overall survival for all patients.

About renal cell cancer / carcinoma
There are approximately 273,000 new cases of Renal Cell Cancer (RCC) diagnosed worldwide each year, representing approximately two percent of all cancers. The therapeutic effect of existing treatments, called directed therapies, is often of short duration, with limited survival rate gain. With no alternatives to these therapies, there exists a relatively large unsatisfied medical need for new treatments that are effective, more cost-efficient and have less unwanted side effects.

About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX) is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Correction: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:47Pressmeddelande

BIMobject comes in at place 185 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

BIMobject AB: Rättelse: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:47Pressmeddelande

BIMobject hamnar på plats 185 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017 valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och gru

BIMobject AB: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:18Pressmeddelande

BIMobject hamnar på plats 158 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och grun

BIMobject AB: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:18Pressmeddelande

BIMobject comes in at place 158 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

SD-WAN Market Leader, Aryaka, Releases First EMEA Edition of its State of SD-WAN Connectivity Report18.12.2017 15:06Pressmeddelande

Research finds up to 20x cloud and SaaS application performance improvements when connecting via private network-based SD-WANs versus the public Internet LONDON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, has released its first EMEA Edition of the State of SD-WAN Connectivity report that analyses the performance of SD-WAN deployments over the Internet as compared with those delivered over global private networks. The report highlights specific application response times between various European, Middle East, Asia-Pacific and Americas locations, as well as key factors that impact the performance of cloud and SaaS applications. This research helps IT leaders in Europe, Middle East and Africa (EMEA) to evaluate the best underlying connectivity for their SD-WAN deployments to ensure fast, reliable and consistent performance for all on-premises, cloud and SaaS applications, including voice, video, and data. The report reveals significant dif

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressmeddelande

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum